Regenerative Biotechnology
Célula Natural Killer Heterologas
Heterologous Natural Killer cells pretreated with nivolumab for antitumor immunotherapy.
Injectable solution of heterologous Natural Killer cells pretreated with nivolumab that enhances innate and adaptive immune response against tumor cells.
Composition
Heterologous Natural Killer cells with nivolumab.
Pharmaceutical form
Injectable solution.
Presentation
Single-dose vial, 4 ml.
Therapeutic properties
Antitumor cytotoxic activity through NK cell activation and PD-1 pathway blockade, enhancing immune response.
- Recognition of tumor cells.
- Induction of tumor apoptosis.
- Blockade of tumor immune evasion.
- Enhanced antitumor cytotoxicity.
- Activation of innate immunity.
- Stimulation of adaptive response.
- Reduction of tumor growth.
- Support in resistant neoplasms.
Mechanism of action & Clinical data
NK cells induce tumor cytotoxicity and, with PD-1 blockade, restore immune recognition of malignant cells.